Related Experiment Videos
Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus
1Department of Chemical Pathology, Guy's, King's and St. Thomas' School (King's College London), St. Thomas' Hospital Campus, UK.
Insights
Systemic lupus erythematosus (SLE) patients frequently experience early cardiovascular disease (CVD) and hyperlipidemia. This review explores how SLE autoimmunity accelerates atherosclerosis and suggests lipid-lowering therapies may reduce cardiovascular risk in these patients.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) is linked to premature cardiovascular disease (CVD).
- Hyperlipidemia is a common comorbidity in SLE patients.
- Autoimmunity in SLE may contribute to accelerated atheroma progression.
Purpose of the Study:
- To review evidence on increased prevalence of coronary heart disease (CHD) and hyperlipidemia in SLE.
- To examine mechanisms linking SLE autoimmunity to accelerated atheroma.
- To explore the potential role of lipid-lowering therapies in reducing CHD incidence in SLE.
Main Methods:
- Literature review of studies on SLE, cardiovascular disease, and hyperlipidemia.
- Analysis of proposed mechanisms for accelerated atheroma in SLE.
- Evaluation of existing data on lipid-lowering therapies in SLE patients.
Main Results:
- Evidence suggests a higher prevalence of CHD and hyperlipidemia in SLE.
- Autoimmune processes in SLE appear to accelerate atherosclerosis.
- Lipid-lowering therapies show potential for mitigating cardiovascular risk in SLE.
Conclusions:
- SLE significantly increases the risk of early-onset cardiovascular disease.
- Understanding the interplay between autoimmunity and atherogenesis is crucial.
- Lipid-lowering interventions warrant further investigation for managing cardiovascular risk in SLE.
Abstract:
Systemic lupus erythematosus is commonly associated with early onset cardiovascular disease and is often associated with hyperlipidaemia. This review examines the evidence for an increased prevalence of both CHD and hyperlipidaemia in SLE and mechanisms by which autoimmunity in SLE could accelerate the progression of atheroma. It postulates how lipid lowering therapies used in cardiological disease might help reduce the incidence of CHD in SLE.